Yahoo · Sep 15, 2026
Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?
Here is how Delcath Systems, Inc. (DCTH) and Encompass Health (EHC) have performed compared to their sector so far this year.
DC
NASDAQ · DCTH
Delcath Systems, Inc.
Healthcare · Medical - Devices
$16.22
Up+$0.03 (+0.18%)
Updated Sep 17, 2026, 11:17 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 361.31M
- P/E ratio
- 166.87
- Dividend yield
- 0.00%
- 52-week range
- $8.78 – $17.42
- Volume
- 463.17K
- Avg. volume
- 894.08K
Price performance
DCTH price history
1M range · 20 trading sessions · Daily adjusted prices
DCTH closed at $16.22 after 20 trading sessions, down 5.42% for the selected period.
- Last close
- $16.22
- Period change
- -5.42%
- Period low
- $15.80
- Period high
- $17.15
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $16.16 | $16.485 | $16.06 | $16.22 | 463.17K |
| Sep 15, 2026 | $16.49 | $16.49 | $15.88 | $16.17 | 323.16K |
| Sep 14, 2026 | $15.95 | $16.51 | $15.95 | $16.44 | 503.42K |
| Sep 11, 2026 | $15.99 | $16.00 | $15.73 | $15.91 | 347.06K |
| Sep 10, 2026 | $16.12 | $16.12 | $15.68 | $15.80 | 303.59K |
| Sep 9, 2026 | $16.08 | $16.27 | $15.90 | $15.98 | 384.68K |
| Sep 8, 2026 | $16.26 | $16.37 | $15.92 | $16.08 | 259.24K |
| Sep 4, 2026 | $16.32 | $16.49 | $16.2501 | $16.48 | 180.92K |
| Sep 3, 2026 | $16.69 | $16.69 | $16.28 | $16.48 | 268.65K |
| Sep 2, 2026 | $16.39 | $16.781 | $16.315 | $16.58 | 448.65K |
| Sep 1, 2026 | $16.48 | $16.55 | $16.235 | $16.40 | 360.38K |
| Aug 31, 2026 | $16.27 | $16.48 | $16.10 | $16.46 | 402.69K |
| Aug 28, 2026 | $16.32 | $16.49 | $16.15 | $16.34 | 491.08K |
| Aug 27, 2026 | $16.38 | $16.54 | $16.23 | $16.39 | 402.57K |
| Aug 26, 2026 | $16.90 | $16.94 | $16.35 | $16.40 | 367.18K |
| Aug 25, 2026 | $16.90 | $17.125 | $16.80 | $16.92 | 503.72K |
| Aug 24, 2026 | $17.11 | $17.14 | $16.68 | $16.75 | 417.05K |
| Aug 21, 2026 | $16.84 | $17.15 | $16.60 | $17.14 | 509.06K |
| Aug 20, 2026 | $17.05 | $17.15 | $16.61 | $16.75 | 385.92K |
| Aug 19, 2026 | $17.14 | $17.34 | $16.8917 | $17.15 | 531.09K |
Latest DCTH news
The latest Smart Investors Daily articles mentioning DCTH.
Stock researchCompany · Overview
DCTH research
Overview
Company profile and research snapshot.
Company profile
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $25.00
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Feb 26, 2026 | BTIG | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 5, 2025 | Stephens & Co. | Overweight | — |
News briefing
Generated Sep 17, 2026, 9:22 PM
Why Is DCTH Moving Slightly Higher Today?
Delcath Systems (DCTH) is up a modest $0.03 (0.18%) today, reflecting a cautious market sentiment as investors reassess the medical device sector. The minimal gain suggests limited near-term catalysts, though recent comparative analysis of DCTH against broader medical stock performance is drawing some attention.
Bottom line: DCTH's minor gain reflects a market in holding pattern, waiting for more definitive company catalysts or clinical data to drive conviction. Investors should monitor upcoming regulatory decisions, clinical trial results, and reimbursement developments, as these will likely determine whether the company can sustain its relative medical stock positioning.
Yahoo · Sep 11, 2026
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y., September 11, 2026--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026.
Yahoo · Sep 11, 2026
Delcath’s (DCTH) Liver Cancer Device Keeps Growing, But At A Cost
On August 6, Delcath Systems (NASDAQ:DCTH) reported second-quarter results that showed the company selling more of its liver cancer treatment than ever, even as the cost of running the business climbed just as fast. The interventional oncology company posted total revenue of $29.1 million, up from $24.2 million a year earlier, and used the report […]
Yahoo · Sep 8, 2026
Keep Portfolio Volatility in Check With VLO, PBF, FET & DCTH
VLO, PBF, FET and DCTH screen as low-beta picks as volatility rises, backed by refining, energy-equipment and liver-cancer growth drivers.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
